Asia Study Group of Prostate Cancer (A-CaP Study)

Launched by JAPAN STUDY GROUP OF PROSTATE CANCER · Aug 16, 2016

Keywords

ClinConnect Summary

The A-CaP will collect information in a linkable anonymized format from all medical institutions in Asian countries participating in the study and will engage in data analysis. J-CaP which has previous experience of engaging in a similar study in 2010 wll be a sponsor for A-CaP study, the aggregated results of which have been reported. The registration period for this study will be three years followed by 7 years of follow-up study, and research will be implemented across a wider range of Asian countries, with new institutions participating for the purposes of this study. As this study will...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients who have received a histopathological diagnosis of prostate cancer between January 1,2016,and December 31,2018.
• • Patients who, having received a diagnosis within the abovementioned period, began initial treatment for prostate cancer(including active surveillance).
• • Patients who are either hospitalized as outpatients.
• Exclusion Criteria:
• • • Patients for whom information about the time of diagnosis, including histopathological diagnosis, cannot be acquired.